Clinical Trials Browser

Terminated × ASTX-660 × Other hematologic neoplasm × Clear all

NCT04155580 2024-08-02

A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Phase 1 Terminated

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic